Education
About Us
Working with TipRanks
Follow Us
BioStem Technologies (BSEM)
OTHER OTC:BSEM
Top Page
BioStem Technologies
(OTC:BSEM)
Select Model
Select Model
Rating:68Neutral
Price Target:
$4.00
▼(-17.18% Downside)
The score is driven primarily by solid financial profitability/cash generation and low leverage, supported by an attractive low P/E valuation. These positives are tempered by weak technical trend signals (price below major moving averages) and earnings-call risks around revenue decline and pricing pressure despite improving volumes and ongoing positive adjusted EBITDA.
Positive Factors
High gross margins
Sustained gross margins above industry peers provide durable cash generation and buffer against revenue volatility. High margins support reinvestment in R&D, operational scale-up and margin preservation even if selling prices fall, underpinning long-term profitability and strategic optionality.
Consistent positive adjusted EBITDA
Seven consecutive quarters of positive adjusted EBITDA indicate recurring operational profitability and disciplined cost control. This consistency enhances funding capacity for growth initiatives, supports an uplisting strategy, and reduces execution risk compared with peers lacking persistent operating cash generation.
Low leverage
A low debt-to-equity ratio gives the company financial flexibility to pursue strategic investments, absorb reimbursement or pricing shocks, and finance expansion (e.g., Medicaid/VA channels or HQ land) without risking solvency. It lowers refinancing risk over the medium term.
Negative Factors
Declining revenue trend
A multi-quarter and year-over-year revenue decline signals structural demand or pricing issues that can erode scale economics. Persistent top-line contraction reduces ability to fund growth, compresses margins through mix effects, and raises execution risk for strategic initiatives over coming quarters.
Pricing pressure from reimbursement model
Sustained reimbursement-driven price adjustments reduce realized unit revenue and can persist as payers and competitors optimize pricing. Over the medium term this undermines revenue per sale and requires volume or cost improvements to maintain earnings, adding structural margin risk.
Recent cash balance decline tied to investments
Declining cash from strategic land purchase and collection timing reduces near-term liquidity cushions. While still positive, continued cash drawdowns or slower collections may constrain capital for operations or require external financing, increasing financial execution risk over the next several quarters.
BioStem Technologies (BSEM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$68.62M
Dividend YieldN/A
Average Volume (3M)73.19K
Price to Earnings (P/E)4.5
Beta (1Y)2.00
Revenue Growth11.78%
EPS Growth37.44%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.03
Shares Outstanding16,338,436
10 Day Avg. Volume113,497
30 Day Avg. Volume73,185
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)5.54
Price to Sales (P/S)0.75
P/FCF Ratio9.42
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue0.14
Enterprise Value/Gross Profit0.15
Enterprise Value/Ebitda1.85
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.29
Revenue Forecast (FY)$271.30M
BioStem Technologies Business Overview & Revenue Model
Company DescriptionBioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.
How the Company Makes MoneyBioStem Technologies generates revenue through multiple key streams. Primarily, the company earns income from the processing and storage fees associated with stem cell collection services, where parents pay to store umbilical cord blood and tissue for potential future medical use. Additionally, BSEM monetizes its proprietary stem cell therapies and related products sold to healthcare providers and research institutions. Strategic partnerships with hospitals, clinics, and research organizations further enhance revenue opportunities through collaborative research and development projects. The company may also engage in licensing agreements for its technologies, providing another avenue for income generation.
BioStem Technologies Earnings Call Summary
Earnings Call Date:Nov 13, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Apr 06, 2026
Earnings Call Sentiment Neutral
BioStem Technologies demonstrated resilience and strategic growth through increased product volume, consistent positive adjusted EBITDA, and strong gross margins. The company successfully expanded into new markets despite facing revenue and cash balance declines due to competitive pricing pressures and strategic investments.Q3-2025 Updates
Positive Updates
Increased Product Volume
Despite a challenging pricing environment, BioStem sold 40% more products on a volume basis compared to the previous quarter, indicating strong underlying demand and market share growth.
Seventh Consecutive Quarter of Positive Adjusted EBITDA
BioStem achieved its seventh consecutive quarter of positive adjusted EBITDA, highlighting the resilience and strength of its business model.
Strong Gross Margins
BioStem maintained industry-leading gross margins, with a gross profit of $9.3 million, representing a gross margin of 88.5% for Q3.
Successful FDA Inspection
BioStem's facility passed a follow-up and routine FDA inspection with no nonconformance observations, indicating a strong quality system and readiness to scale production.
Expansion into New Markets
BioStem expanded into the Medicaid market with initial success in Medi-Cal and Texas Medicaid, and partnered with a Service-Disabled Veteran-Owned Small Business to serve the VA.
Negative Updates
Decreased Revenue
Revenue for the quarter totaled $10.5 million, down from $11 million in the previous quarter and $18.4 million in Q3 of 2024, primarily due to competition from higher-priced products and a lower selling price to Venture.
Cash Balance Decline
BioStem's cash balance decreased from $30.8 million at the end of Q2 to $27.2 million at the end of Q3, largely due to the purchase of land for future headquarters and the timing of collections from Venture Medical.
Company Guidance
During the BioStem Technologies Third Quarter 2025 Earnings Call, CEO Jason Matuszewski and CFO Brandon Poe highlighted several key metrics and strategic initiatives. The company reported Q3 revenue of $10.5 million, down from $11 million in Q2 2025 and $18.4 million in Q3 2024, despite a 40% increase in product volume, attributed to price adjustments under the ASP Plus 6 reimbursement model. Gross profit was $9.3 million, with a gross margin of 88.5%, compared to 93.8% in the prior quarter. Operating expenses were reduced to $7.8 million from $10.2 million in Q2 2025. The company maintained a cash balance of $27.2 million at the end of Q3, supporting its strategic initiatives, including a future uplisting to NASDAQ and expansion into new markets such as Medicaid and the Department of Veteran Affairs. BioStem also reported seven consecutive quarters of positive adjusted EBITDA, underscoring its financial resilience and operational efficiency.BioStem Technologies Financial Statement Overview
Summary
Strong profitability and cash generation (gross margins consistently above 90% historically; positive operating and free cash flow with high FCF-to-net income of 0.98) and low leverage (debt-to-equity 0.11) are positives. Offsetting these are declining TTM revenue growth (-7.58%), slowing free cash flow growth (-3.84%), and reduced efficiency as ROE fell to 65.93%.Income Statement
BioStem Technologies shows strong gross profit margins consistently above 90%, indicating efficient cost management. However, recent revenue growth has declined by 7.58% in the TTM, which is a concern. The net profit margin remains healthy at 10.98%, reflecting profitability, but the decline in EBIT and EBITDA margins suggests potential operational challenges.75
Positive
Balance Sheet
The company's debt-to-equity ratio is low at 0.11, indicating prudent leverage management. However, the return on equity has decreased from 78% to 65.93% in the TTM, suggesting reduced efficiency in generating returns from equity. The equity ratio is not provided, but the overall stability appears moderate.65
Positive
Cash Flow
Operating cash flow and free cash flow are positive, with a high free cash flow to net income ratio of 0.98, indicating strong cash generation relative to profits. However, the free cash flow growth rate has declined by 3.84% in the TTM, which could impact future liquidity.70
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 307.26M | 301.83M | 16.69M | 6.88M | 4.34M | 2.52M |
| Gross Profit | 297.89M | 287.86M | 15.42M | 5.99M | 2.87M | 1.25M |
| EBITDA | 23.39M | 31.49M | -7.55M | -6.52M | -602.00K | -2.25M |
| Net Income | 26.26M | 31.88M | -8.48M | -7.07M | -1.45M | -2.39M |
Balance Sheet | ||||||
| Total Assets | 112.61M | 140.55M | 14.56M | 3.47M | 2.67M | 2.67M |
| Cash, Cash Equivalents and Short-Term Investments | 30.84M | 22.83M | 239.41K | 772.14K | 340.33K | 100.70K |
| Total Debt | 3.59M | 4.50M | 4.77M | 5.21M | 4.83M | 5.63M |
| Total Liabilities | 64.52M | 99.67M | 15.90M | 7.42M | 8.47M | 8.30M |
| Stockholders Equity | 48.09M | 40.88M | -1.34M | -4.08M | -5.96M | -5.80M |
Cash Flow | ||||||
| Free Cash Flow | 26.36M | 24.05M | -3.60M | -2.11M | -152.29K | -585.25K |
| Operating Cash Flow | 27.11M | 24.48M | -3.50M | -1.64M | -109.44K | -581.57K |
| Investing Cash Flow | -2.00M | -1.68M | -210.33K | -469.48K | -7.85K | -3.69K |
| Financing Cash Flow | -840.43K | -206.78K | 3.18M | 597.71K | 357.42K | 541.52K |
BioStem Technologies Technical Analysis
Negative
4.83
Price Trends
4.20
Negative
4.70
Negative
8.18
Negative
Market Momentum
0.08
Positive
42.56
Neutral
21.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BSEM, the sentiment is Negative. The current price of 4.83 is above the 20-day moving average (MA) of 4.27, above the 50-day MA of 4.20, and below the 200-day MA of 8.18, indicating a bearish trend. The MACD of 0.08 indicates Positive momentum. The RSI at 42.56 is Neutral, neither overbought nor oversold. The STOCH value of 21.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BSEM.
BioStem Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $68.62M | 4.51 | 55.46% | ― | 11.78% | 37.44% | |
59 Neutral | $145.86M | 6.62 | 19.23% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $394.49M | -10.34 | -64.12% | ― | ― | -29.73% | |
49 Neutral | $164.85M | -3.03 | -271.32% | ― | -75.77% | -31.24% | |
46 Neutral | $372.29M | -0.64 | -51.70% | ― | -100.00% | -0.58% | |
46 Neutral | $209.06M | -1.69 | -46.09% | ― | -80.88% | -388.61% |
* Healthcare Sector Average
BSEM
BioStem Technologies
3.84
-11.88
-75.59%
CBIO
Crescent Biopharma
13.98
-12.31
-46.82%
VYGR
Voyager Therapeutics
3.67
-1.55
-29.69%
DMAC
Diamedica Therapeutics
7.42
1.62
27.93%
BDTX
Black Diamond Therapeutics
2.40
0.16
7.14%
IPHA
Innate Pharma
1.81
0.05
2.55%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.